Author

Jonathan Stuart Serody

University of North Carolina at Chapel HillORCID 0000-0003-4568-1092Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Assay:scRNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

Charles M. PerouiD· 2 shared Alex J. SmithiD· 1 shared Alexander V. KabanoviD· 1 shared Chaemin LimiD· 1 shared Charlotte Helena RivasiD· 1 shared Diego A. PedrozaiD· 1 shared Duhyeong HwangiD· 1 shared Fengshuo LiuiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Charles M. PerouORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCancer Immunology ResearchPeer-reviewedAug 17, 2026

MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable anti-tumor immunity in triple negative breast cancer

Alex J. Smith, Zachary Schrank, Nan Guan…·Jeffrey M. Rosen

This paper shows that combining MERTK inhibition with cyclophosphamide enhances anti-tumor immunity in basal-like TNBC by reprogramming macrophages and promoting CD4 T cell responses.

DOI 10.1158/2326-6066.cir-26-0278

mousescRNA-seq

𝕏 PostBluesky

ImmunologyBiomaterialsPeer-reviewedAug 8, 2024

Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy

Mostafa Yazdimamaghani, Oleg V. Kolupaev, Chaemin Lim…·Jonathan Stuart Serody

This study shows that combining nanoformulated TLR7/8 agonist and PI3K delta inhibitor with radiotherapy improves anti-tumor activity in TNBC by modulating the tumor microenvironment.

35 citationstop 3%

mousebulk RNA-seq

𝕏 PostBluesky